COST

987.2

+0.21%↑

PG

154.92

+0.11%↑

KO

70.54

+0.27%↑

PM

168.23

-0.41%↓

PEP

146.45

+1.6%↑

COST

987.2

+0.21%↑

PG

154.92

+0.11%↑

KO

70.54

+0.27%↑

PM

168.23

-0.41%↓

PEP

146.45

+1.6%↑

COST

987.2

+0.21%↑

PG

154.92

+0.11%↑

KO

70.54

+0.27%↑

PM

168.23

-0.41%↓

PEP

146.45

+1.6%↑

COST

987.2

+0.21%↑

PG

154.92

+0.11%↑

KO

70.54

+0.27%↑

PM

168.23

-0.41%↓

PEP

146.45

+1.6%↑

COST

987.2

+0.21%↑

PG

154.92

+0.11%↑

KO

70.54

+0.27%↑

PM

168.23

-0.41%↓

PEP

146.45

+1.6%↑

Search

Hims & Hers Health Inc

Открыт

СекторПотребительские товары
(защитный сектор)

47.62 -6.72

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

47.3

Макс.

51.23

Ключевые показатели

By Trading Economics

Доход

23M

49M

Продажи

105M

586M

P/E

Средняя по отрасли

91.812

26.17

Рентабельность продаж

8.444

Сотрудники

1,637

EBITDA

48M

66M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-1.17% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

3 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

5B

14B

Предыдущая цена открытия

54.34

Предыдущая цена закрытия

47.62

Новостные настроения

By Acuity

50%

50%

62 / 150 Рейтинг в Consumer defensive

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Hims & Hers Health Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 авг. 2025 г., 00:05 UTC

Популярные акции

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

29 апр. 2025 г., 12:54 UTC

Главные движущие силы рынка

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4 апр. 2025 г., 22:38 UTC

Популярные акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 апр. 2025 г., 23:15 UTC

Главные движущие силы рынка

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 февр. 2025 г., 15:33 UTC

Главные движущие силы рынка

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 нояб. 2024 г., 19:07 UTC

Главные движущие силы рынка

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 окт. 2024 г., 15:02 UTC

Главные движущие силы рынка

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

5 авг. 2025 г., 20:44 UTC

Отчет

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 авг. 2025 г., 18:17 UTC

Отчет

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 авг. 2025 г., 17:26 UTC

Отчет
Приобретения, слияния, поглощения

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5 авг. 2025 г., 15:25 UTC

Отчет

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 авг. 2025 г., 11:27 UTC

Отчет

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 авг. 2025 г., 10:55 UTC

Отчет

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 авг. 2025 г., 10:36 UTC

Отчет

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

29 июл. 2025 г., 16:55 UTC

Отчет

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

24 июн. 2025 г., 10:26 UTC

Обсуждения рынка

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

3 июн. 2025 г., 15:03 UTC

Приобретения, слияния, поглощения

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

7 мая 2025 г., 13:56 UTC

Отчет

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6 мая 2025 г., 14:24 UTC

Отчет

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30 апр. 2025 г., 09:30 UTC

Главные новости

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2 апр. 2025 г., 16:53 UTC

Главные новости

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 мар. 2025 г., 15:54 UTC

Главные новости

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 февр. 2025 г., 23:20 UTC

Отчет

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 февр. 2025 г., 12:00 UTC

Главные новости

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 дек. 2024 г., 17:16 UTC

Главные новости

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 дек. 2024 г., 15:14 UTC

Главные новости

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 дек. 2024 г., 15:02 UTC

Главные новости

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 дек. 2024 г., 13:47 UTC

Главные новости

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 дек. 2024 г., 07:00 UTC

Главные новости

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 окт. 2024 г., 14:45 UTC

Главные новости

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Hims & Hers Health Inc Прогноз

Целевая цена

By TipRanks

-1.17% падение

Прогноз на 12 месяцев

Средняя 51.33 USD  -1.17%

Максимум 85 USD

Минимум 28 USD

Основано на мнении 11 аналитиков Wall Street, спрогнозировавших целевые цены для Hims & Hers Health Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

11 ratings

3

Покупка

6

Удержание

2

Продажа

Техническая оценка

By Trading Central

36.685 / 52.35Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bullish Evidence

Настроения

By Acuity

62 / 150Рейтинг в Потребительские товары<br>(защитный сектор)

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.